YHYoshihisa Hiromine

Yoshihisa Hiromine

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshihisa Hiromine has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Metachronous multiple insulinomas in oculo-facio-cardio-dental syndrome harboring a novel BCOR deletion: a case report with review of literature

    by Shinsuke Noso, Hiroki Miki, Yoshihisa Hiromine, Naru Babaya, Yasunori Taketomo, Sawa Yoshida, Katsuya Ami, Ippei Matsumoto, Norikazu Maeda

    Oculo-facio-cardio-dental (OFCD) syndrome is a rare X-linked dominant disorder caused by pathogenic variants in the BCOR gene and is characterized by distinctive craniofacial, ocular, cardiac, and dental abnormalities. Although OFCD syndrome is a well-defined developmental disorder, its association with endocrine tumors has not been clearly established. We report a female patient with genetically confirmed OFCD syndrome harboring a novel heterozygous deletion in BCOR who developed metachronous multiple insulinomas. The patient presented with recurrent hypoglycemic episodes, and pancreatic neuroendocrine tumors were detected at different time points, necessitating repeated surgical interventions. Histopathological examination confirmed insulinoma in each resected lesion. Comprehensive clinical and pathological evaluations revealed no features suggestive of other known hereditary insulinoma-associated syndromes, including multiple endocrine neoplasia type 1. Previous reports have described either recurrent insulinoma without genetic confirmation of OFCD syndrome or multiple insulinomas without documented recurrence in genetically confirmed cases. In contrast, the present case uniquely demonstrates metachronous development of multiple insulinomas in association with a novel BCOR deletion. Given the role of BCOR in transcriptional repression and developmental regulation, this case suggests a potential contribution of BCOR dysfunction to pancreatic neuroendocrine tumorigenesis. Our findings expand the phenotypic and genotypic spectrum of OFCD syndrome and underscore the importance of long-term surveillance and further accumulation of cases to clarify tumor predisposition in this rare disorder.

  • Association between plasma mid‐regional pro‐adrenomedullin levels and muscle properties

    by Hiroshi Akasaka, Yasuharu Tabara, Kazuki Fukuma, Yoshihisa Hiromine, Yasunori Takata, Masahiro Fukuda, Tomohiro Katsuya, Masafumi Ihara, Haruhiko Osawa, Hiroshi Ikegami, et al.

    Aim: Adrenomedullin exerts a vasodilative effect and is thought to be associated with skeletal muscle properties by regulating microcirculation. This cross‐sectional study aimed to clarify the possible association in older adults aged ≥65 years.Methods: The study population included 978 community residents (mean age 71.5 years) who participated in the medical checkup. Mid‐thigh skeletal muscle mass and fat infiltration into the muscle was assessed using computed tomography images. Plasma levels of mid‐regional pro‐adrenomedullin, a stable fragment derived from pro‐adrenomedullin in a 1:1 ratio with adrenomedullin, were measured using blood drawn at the medical checkup, and quartiles were calculated for analysis.Results: Mid‐regional pro‐adrenomedullin did not show significant association with the mid‐thigh skeletal muscle cross‐sectional area, an index of muscle mass (Q1: 217 ± 50, Q2: 218 ± 48, Q3: 215 ± 48, Q4: 212 ± 45 cm2, P = 0.544). Muscle subtype analysis showed that mid‐regional pro‐adrenomedullin was inversely associated with fewer fat (high intensity) muscle areas and positively associated with fat‐rich (low intensity) muscle areas, resulting in an inverse association with mean muscle intensity, an index of muscle quality (Q1: 50.3 ± 4.2, Q2: 49.6 ± 4.5, Q3: 49.1 ± 4.3, Q4: 47.1 ± 4.6 HU, P < 0.001). This association remained significant after adjustment of possible covariates, including anthropometric factors and glycemic factors (Q1: reference, Q2: β = −0.078, P = 0.018, Q3: β = −0.099, P = 0.004, Q4: β = −0.180, P < 0.001).Conclusion: Adrenomedullin is associated with muscle quality, but not with muscle mass. Geriatr Gerontol Int 2025; 25: 1418–1424.


  • Open Access

    A 58-Year-Old Man with a History of Autoimmune Thyroiditis Diagnosed with Mucosa-Associated Lymphoid Tissue Lymphoma and Papillary Carcinoma of the Thyroid

    by Naru Babaya, Sawa Yoshida, Shinsuke Noso, Yoshihisa Hiromine, Yasunori Taketomo, Takayuki Kimura, Hiroaki Kakutani, Takao Satou, Hiroshi Ikegami, Norikazu Maeda

    BACKGROUND Mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade B-cell non-Hodgkin's lymphoma. Autoimmune (Hashimoto's) thyroiditis is associated with thyroid MALT lymphoma, but co-existence with papillary thyroid carcinoma (PTC) has been less commonly reported. In this case report, we describe a 58-year-old man who presented with a 6-month history of hoarseness and an enlarged thyroid, and was diagnosed with Hashimoto's thyroiditis, MALT lymphoma, and PTC. CASE REPORT Upon referral to our hospital, he presented with an enlarged goiter and hoarseness. Based on preoperative findings, he was diagnosed with Hashimoto's thyroiditis, PTC in the left lobe, and possible malignant lymphoma in both thyroid lobes. However, whether the lymph node swelling around the neck and ¹⁸F-fluorodeoxyglucose uptake on positron emission tomography near the pancreas were related to the PTC, malignant lymphoma, or both remained unclear. Total thyroidectomy and lymph node dissection were performed to treat the PTC and to aid in the diagnosis of malignant lymphoma; the patient was diagnosed with PTC and MALT lymphoma, and lymphadenopathy was attributed to MALT lymphoma. The patient underwent postoperative chemotherapy with rituximab alone, and remission was maintained nearly 3 years after surgery. CONCLUSIONS This report highlights the association between Hashimoto's thyroiditis and thyroid MALT lymphoma, presents a rare finding of coexistent PTC and lymphadenopathy of initially unknown origin, and underscores the importance of histopathology in the diagnosis of these conditions.


  • Open Access

    High Incidence of Diabetes Mellitus After Distal Pancreatectomy and Its Predictors: A Long-term Follow-up Study

    by Shuzo Imamura, Fumimaru Niwano, Naru Babaya, Yoshihisa Hiromine, Ippei Matsumoto, Keiko Kamei, Yuta Yoshida, Yasunori Taketomo, Sawa Yoshida, Yoshifumi Takeyama, et al.

    Context: Glucose tolerance worsens after distal pancreatectomy (DP); however, the long-term incidence and factors affecting interindividual variation in this worsening are unclear. Objective: To investigate the changes in diabetes-related traits before and after DP and to clarify the incidence of diabetes and its predictors. Methods: Among 493 registered patients, 117 underwent DP. Among these, 56 patients without diabetes before surgery were included in the study. Glucose and endocrine function were prospectively assessed using a 75-g oral glucose tolerance test preoperatively, 1 month after DP, and every 6 months thereafter for up to 36 months. Pancreatic volumetry was performed using multidetector row computed tomography before and after surgery. Results: Insulin secretion decreased and blood glucose levels worsened after DP. Residual pancreatic volume was significantly associated with the reserve capacity of insulin secretion but not with blood glucose levels or the development of diabetes. Among 56 patients, 33 developed diabetes mellitus. The cumulative incidence of diabetes at 36 months after DP was 74.1%. Multivariate Cox regression analysis showed that impaired glucose tolerance as a preoperative factor as well as a decreased insulinogenic index and impaired glucose tolerance at 1 month postoperatively were identified as risk factors for diabetes following DP. Conclusion: Impaired glucose tolerance and reduced early-phase insulin response to glucose are involved in the development of new-onset diabetes after DP; the latter is an additional factor in the development of diabetes and becomes apparent when pancreatic beta cell mass is reduced after DP.


  • Open Access

    Glycemic Excursion and Insulin Action Revealed in a Rare Case of Type 1 Diabetes Complicated with Short Bowel Syndrome

    by Yoshihisa Hiromine, Shinsuke Noso, Naru Babaya, Yasunori Taketomo, Fumimaru Niwano, Yuki Okuda, Sara Yasutake, Tatsuro Minohara, Naonobu Tsuda, Yuichiro Hama, et al.

    We herein report a 52-year-old woman with a rare combination of short bowel syndrome due to massive resection of the small intestine and complete loss of endogenous insulin due to type 1 diabetes. To provide nutritional support, she was treated with total parenteral nutrition with co-administration of insulin, requiring careful matching of insulin and glucose levels. This case report provides insights on glycemic excursion and insulin action in type 1 diabetes, even when both insulin and glucose are administered directly into circulation, and the usual obstacles caused by subcutaneous injection of insulin and oral intake of nutrients are eliminated.

  • Open Access

    Metabolic signatures of β‐cell destruction in type 1 diabetes

    by Shinsuke Noso, Naru Babaya, Yoshihisa Hiromine, Yasunori Taketomo, Fumimaru Niwano, Sawa Yoshida, Hiroshi Ikegami

    Aims/Introduction: In the development of type 1 diabetes, metabolites are significantly altered and might be involved in β‐cell destruction and protection. We aimed to identify new metabolic markers of β‐cell destruction in type 1 diabetes patients.Materials and Methods: A total of 33 participants were recruited for this cross‐sectional observational study: 23 with type 1 diabetes, seven with type 2 diabetes and three healthy controls. Those with type 1 diabetes were further subdivided into three groups: new‐onset, microsecretors and complete lack of endogenous insulin in type 1 diabetes.Results: Metabolomic analysis identified a total of 737 peaks, and partial least square analysis was successful in discriminating between the three groups of type 1 diabetes. Among the factor loadings discriminating type 1 diabetes, 3‐phenylpropionic acid (r = 0.80, P = 4.7E−6) and hypotaurine (r = −0.484, P = 1.9E−2) strongly contributed to identifying new‐onset type 1 diabetes, and 5‐methylcytosine to identifying complete‐lack type 1 diabetes (r = 0.586, P = 6.5E−3). Reporter operating characteristics analysis, including all type 1 diabetes, type 2 diabetes and healthy controls, showed that high 3‐phenylpropionic acid (Pc Pc Pc = 0.002) for the complete‐lack type 1 diabetes.Conclusions: In the present study, metabolic signatures were shown to be useful in identifying type 1 diabetes at different clinical stages, and 3‐phenylpropionic acid and hypotaurine are novel biomarkers for identifying new‐onset type 1 diabetes, suggesting the involvement of the gut bacterial environment, anti‐oxidant mechanisms through the hypotaurine‐taurine pathway and methylated deoxyribonucleic acid fragmentation in the process of β‐cell destruction.


  • Open Access

    Three-Year Observation of Glucose Metabolism After Pancreaticoduodenectomy: A Single-Center Prospective Study in Japan

    by Fumimaru Niwano, Naru Babaya, Yoshihisa Hiromine, Ippei Matsumoto, Keiko Kamei, Yasunori Taketomo, Sawa Yoshida, Yoshifumi Takeyama, Shinsuke Noso, Hiroshi Ikegami

    Context: The glucose tolerance of patients changes considerably from before to after pancreaticoduodenectomy wherein approximately half of the pancreas is resected. Objective: The aim of this prospective study was to investigate the incidence of and risk factors for diabetes after pancreaticoduodenectomy. Methods: This study is a part of an ongoing prospective study, the Kindai Prospective Study on Metabolism and Endocrinology after Pancreatectomy (KIP-MEP) study. Of the 457 patients enrolled to date, 96 patients without diabetes who underwent pancreaticoduodenectomy were investigated in this study. Preoperatively, 1 month post-pancreaticoduodenectomy, and every 6 months thereafter, the glucose metabolism and endocrine function were evaluated using the 75 g oral glucose tolerance test. Various other metabolic, endocrine, and exocrine indices were also examined over a period of up to 36 months. Results: Of the 96 patients analyzed in this study, 33 were newly diagnosed with diabetes. The cumulative diabetes incidence at 36 months following pancreaticoduodenectomy was 53.8%. The preoperative insulinogenic index and ΔC-peptide in the glucagon stimulation test were significantly lower in the progressors to diabetes than in the nonprogressors. Multivariate Cox regression analysis demonstrated that the insulinogenic index was the only significant risk factor for new-onset diabetes. Conclusion: The majority of patients developed new-onset diabetes after pancreaticoduodenectomy, and a low value of the insulinogenic index was suggested to be a risk factor for diabetes. Preoperative assessment for the prediction of the onset of diabetes serves as useful information for patients and is important for postoperative glycemic control and diabetes management in patients who require pancreaticoduodenectomy.


  • Open Access

    Poor glycemic control rather than types of diabetes is a risk factor for sarcopenia in diabetes mellitus: The MUSCLES‐DM study

    by Yoshihisa Hiromine, Shinsuke Noso, Hiromi Rakugi, Ken Sugimoto, Yasunori Takata, Tomohiro Katsuya, Masahiro Fukuda, Hiroshi Akasaka, Haruhiko Osawa, Yasuharu Tabara, et al.

    Aims/Introduction: Though poor glycemic control and insulin treatment are reported to be associated with sarcopenia in type 2 diabetes, type 1 diabetes may be a stronger risk for sarcopenia. We therefore studied the effect of the type of diabetes, glycemic control, and insulin therapy on the prevalence and characteristics of sarcopenia.Materials and Methods: A total of 812 Japanese patients with diabetes (type 1: n = 57; type 2: n = 755) were enrolled in this study. Sarcopenia was defined as low handgrip strength or slow gait speed and low appendicular skeletal muscle mass.Results: Among participants aged ≥65 years, the sarcopenia prevalence rate was higher among patients with type 1 diabetes (20.0%) than among those with type 2 diabetes (8.1%). The prevalence rate of low handgrip strength was higher in type 1 diabetes (50.0%) than in type 2 diabetes (28.7%). In logistic regression analysis, type 1 diabetes was significantly associated with the prevalence of low handgrip strength. In logistic regression analysis, medication with insulin was significantly associated with the prevalence of sarcopenia; this association was not retained after adjusting for HbA1c.Conclusions: The prevalence of sarcopenia in older adult patients was higher in those with type 1 diabetes than in those with type 2 diabetes. Among the components of sarcopenia, the difference was most prominent in the frequency of low handgrip strength. Poor glycemic control rather than type of diabetes or insulin treatment was revealed to be a primary risk factor for sarcopenia in diabetes mellitus.


  • Open Access

    Insulin‐dependent diabetes mellitus in older adults: Current status and future prospects

    by Hiroshi Ikegami, Yoshihisa Hiromine, Shinsuke Noso

    The recent increase in life expectancy has resulted in an increase in the number of older adults with diabetes mellitus. In addition to type 2 diabetes, in which aging is a well‐known risk factor, individuals with type 1 and other types of diabetes are also increasing owing to longevity in the general population and improved prognosis of the disease and comorbidities. Insulin‐dependent state in type 1 diabetes and other types of diabetes, such as diabetes after pancreatectomy, inevitably requires insulin treatment for survival; however, daily injection of insulin is often hampered in older adults due to impaired cognitive function or limited activities of daily living. In this review, we aimed to discuss the current situation of insulin‐dependent diabetes mellitus in older adults and highlight future prospects. Geriatr Gerontol Int 2022; 22: 549–553.


  • Open Access

    Oncocytic Adrenocortical Carcinoma With Low 18F-FDG Uptake and the Absence of Glucose Transporter 1 Expression

    by Naru Babaya, Shinsuke Noso, Yoshihisa Hiromine, Yasunori Taketomo, Fumimaru Niwano, Keisuke Monobe, Shuzo Imamura, Kazuki Ueda, Yuto Yamazaki, Hironobu Sasano, et al.

    Adrenocortical carcinoma (ACC) is a rare tumor, and some histological variants (oncocytic, myxoid, and sarcomatoid ACCs) have been reported in addition to the conventional ACC. Among these subtypes, oncocytic ACC is histologically characterized by the presence of abundant eosinophilic granular cytoplasm in the carcinoma cells owing to the accumulation of mitochondria, which generally yields high 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET). Herein, we report the case of a 21-year-old woman with oncocytic ACC with low FDG uptake on PET scan. Her circulating levels of androgens were high, and androgen-synthesis enzymes were detected in carcinoma cells. The patient also had hypocholesterolemia. However, glucose transporter 1 (GLUT1) was not detected in the tumor, which was considered to account for the low FDG uptake by the tumor. To the best of our knowledge, this is the first case of low FDG uptake by oncocytic ACC without GLUT1 expression. Additionally, since hypocholesterolemia was reported in 3 previous reports of androgen-producing tumors, a possible correlation between androgenicity in adrenal tumors and the development of hypocholesterolemia could be postulated; however, further investigations are needed for clarification. This case highlights important information regarding the diversity of ACC and its impact on hypocholesterolemia.